BIT · ASX

Biotron Limited (ASX:BIT)

AU$0.019

 0.0 (0.0%)
ASX:Live
21/11/2024 04:10:42 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

BIT Overview

BIT Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About BIT

Website

Biotron Limited

Telephone

61.2.9805.0488

Address

Suite 3.3 56 Delhi Road North Ryde, New South Wales (NSW) 2113

Description

Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. It is developing the compound BIT225 for the treatment of HIV-1. The company was founded in February 1999 and is headquartered in North Ryde, Australia.

BIT Price Chart

Key Stats

Market Cap

AU$17.14M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.12

Trade Value (12mth)

AU$26,926.00

1 week

-2.56%

1 month

-17.39%

YTD

-79.57%

1 year

-79.12%

All time high

0.43

Key Fundamentals

EPS 3 yr Growth

-13.60%

EBITDA Margin

N/A

Operating Cashflow

-$4m

Free Cash Flow Return

-243.10%

ROIC

-234.20%

Interest Coverage

-4,706.00

Quick Ratio

0.60

Other Data

Shares on Issue (Fully Dilluted)

902m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

BIT Announcements

Latest Announcements

Date Announcements

19 November 24

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

15 November 24

Revised Continuous Disclosure Policy

×

Revised Continuous Disclosure Policy

12 November 24

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

12 November 24

Cancel - Application for quotation of securities - BIT

×

Cancel - Application for quotation of securities - BIT

12 November 24

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

30 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

25 October 24

Typographical error

×

Typographical error

24 October 24

Option Expiry Notice

×

Option Expiry Notice

22 October 24

Annual Report/Notice of AGM/Proxy Form

×

Annual Report/Notice of AGM/Proxy Form

14 October 24

$1.8M R&D Rebate Received

×

$1.8M R&D Rebate Received

25 September 24

Response to ASX Aware Query

×

Response to ASX Aware Query

06 September 24

BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL

×

BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL

30 August 24

Full Year Statutory Accounts and Appendix 4E

×

Full Year Statutory Accounts and Appendix 4E

30 August 24

Corporate Governance Statement

×

Corporate Governance Statement

30 August 24

Appendix 4G

×

Appendix 4G

15 August 24

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

31 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

22 July 24

Application for quotation of securities - BIT

×

Application for quotation of securities - BIT

11 July 24

Letter to Shareholders

×

Letter to Shareholders

26 June 24

Webinar Investors Presentation

×

Webinar Investors Presentation

25 June 24

BIOTRON CLINICAL TRIAL RESULTS WEBINAR

×

BIOTRON CLINICAL TRIAL RESULTS WEBINAR

19 June 24

BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives

×

BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives

23 May 24

Change of Share Registry address

×

Change of Share Registry address

26 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

05 April 24

POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV

×

POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV

BIT Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.6 -13.2 11.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.3 -3.7 0.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.7 -15.4 -10.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.00 0.00 -0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.7 133.4 -107.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 725 821 902 Lock Lock Lock
Basic m Lock Lock Lock Lock 725 821 902 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 5 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4.4 4.2 6.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -3 -5 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.0 -82.7 -2.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -5 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 35.6 -81.3 -2.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -3 -5 -5 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.9 -25.6 1.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -3 -4 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 6 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -3 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.6 -35.1 -8.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 4 0 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 2 4 0 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -4 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 1 3 0 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 1 3 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.6 180.0 -107.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -145.9 -84.5 -696.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -254.6 -110.1 1,408.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -110.3 -229.7 -345.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -111.3 -161.9 -234.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -97.5 -152.5 -243.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -541.5 -1,138.2 -4,706.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.6 0.8 0.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -152.3 -124.2 158.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.3 4.2 0.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.3 4.2 0.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.8 98.8 92.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -324.5 -344.2 -483.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -145.9 -84.5 -696.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.7 1.3 -2.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -254.6 -110.1 1,408.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -254.6 -110.1 1,408.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,811.4 2,510.3 2,572.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,811.4 -2,510.3 -2,572.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

BIT Shortsell

Frequently Asked Questions

The current share price of Biotron Limited (BIT:ASX) is AU$0.019.
The 52-week high share price for Biotron Limited (BIT:ASX) is AU$0.12.
The 52-week low share price for Biotron Limited (BIT:ASX)? is AU$0.02.
Biotron Limited (BIT:ASX) does not pay a dividend.
Biotron Limited (BIT:ASX) does not pay a dividend.
Biotron Limited (BIT:ASX) has a franking level of 0.0%.
Biotron Limited (BIT:ASX) is classified in the Healthcare.
The current P/E ratio for Biotron Limited (BIT:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.